Semin intervent Radiol 2019; 36(04): 343-348
DOI: 10.1055/s-0039-1696648
How I Do It
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy

Ahmed Gabr
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
,
Ahsun Riaz
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
,
Samdeep Mouli
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
,
Kush Desai
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
,
Bartley Thornburg
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
,
Riad Salem
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
2   Division of Transplantation, Department of Surgery, Comprehensive Transplant Center, Northwestern University, Chicago, Illinois
3   Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
,
Robert J. Lewandowski
1   Section of Interventional Radiology, Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
2   Division of Transplantation, Department of Surgery, Comprehensive Transplant Center, Northwestern University, Chicago, Illinois
3   Division of Hematology and Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
31 October 2019 (online)

Preview

Surgical resection is regarded as the first-line curative treatment for early-stage hepatocellular carcinoma (HCC). However, the lack of sufficient future liver remnant (FLR) in many patients would preclude them from surgical candidacy. Yttrium-90 radiation lobectomy (RL) has been established over the past decade as an effective method to achieve tumor control as well as achieving FLR hypertrophy, while embedding a test-of-time. Most recently, Yttrium-90 radiation segmentectomy (RS) has been proven potentially curative in early-stage HCC. In this article, we highlight a modified radiation lobectomy (mRL) which is a combined approach of RL and RS that aims at concurrent achievement of complete tumor necrosis and FLR hypertrophy.

Radioembolization has historically been employed in the salvage setting for the treatment of unresectable hepatic malignancies. In this approach, lobar hepatic therapies have been found to offer palliative intent.[1] Observations of an atrophy–hypertrophy complex following this lobar therapy have led to a concept termed “radiation lobectomy”; the treated hepatic lobe will atrophy following radioembolization and the contralateral, untreated, hepatic lobe provides compensatory hypertrophy. This finding has allowed for the application of RL as an alternative to portal vein embolization (PVE), particularly in HCC, which can provide concurrent cancer therapy while promoting hypertrophy of the contralateral FLR for planned surgical resection in patients initially presenting with an FLR insufficient to sustain hepatic function postoperatively.[2] [3] [4]

Described in 2010, RS[5] is a technique increasingly used to treat liver tumors in a segmental rather than lobar fashion. RS has demonstrated safety and efficacy, with good imaging response rates, long time to tumor progression posttreatment, and high rates of explant complete pathologic necrosis.[6] [7] More recently, segmental radioembolization with glass microspheres has been described with curative intent in patients with unresectable HCC.[8]

In this article, we highlight a modified approach to RL combining both lobar and segmental Y90 delivery to promote curative tumor therapy while inducing contralateral hypertrophy to facilitate surgical resection. These approaches have been most commonly performed and reported in the literature employing glass microsphere radioembolization (TheraSphere, Biocompatibles UK Ltd) for patients with unresectable HCC.[9]